Regulation of Mcl-1 alternative splicing by hnRNP F, H1 and K in breast cancer cells

References

• Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071–1080.
   PubMed Web of Science ®Google Scholar
• Correia C, Lee SH, Meng XW, et al. Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015;1853:1658–1671.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.
   PubMed Web of Science ®Google Scholar
• Delbridge AR, Grabow S, Strasser A, et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16:99–109.
   PubMed Web of Science ®Google Scholar
• Williams MM, Cook RS. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget. 2015;6:3519–3530.
   PubMedGoogle Scholar
• Beroukhim R, Mermel C, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.
   PubMed Web of Science ®Google Scholar
• Cho-Vega J, Rassidakis G, Admirand J, et al. MCL-1 expression in B-cell non-Hodgkin’s lymphomas. Hum Pathol. 2004;35:1095–1100.
   PubMed Web of Science ®Google Scholar
• Aichberger K, Mayerhofer M, Krauth M, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005;105:3303–3311.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44:151–157.
   PubMed Web of Science ®Google Scholar
• Ding Q, He X, Xia W, et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007;67:4564–4571.
   PubMed Web of Science ®Google Scholar
• Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4:232–245.
   PubMed Web of Science ®Google Scholar
• Thrane S, Pedersen AM, Thomsen MB, et al. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene. 2015;34:4199–4210.
   PubMed Web of Science ®Google Scholar
• Shketa LCA, Toutant J, Rendos H, et al. Regulation of alternative splicing and the case of Bcl-x. Pak J Biochem Mol Biol. 2015;42:27–38.
   Google Scholar
• Cloutier P, Toutant J, Shkreta L, et al. Antagonistic effects of the SRp30c protein and cryptic 5ʹ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. J Biol Chem. 2008;283:21315–21324.
   PubMed Web of Science ®Google Scholar
• Garneau D, Revil T, Fisette JF, et al. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem. 2005;280:22641–22650.
   PubMed Web of Science ®Google Scholar
• Moore M, Wang Q, Kennedy C, et al. An alternative splicing network links cell-cycle control to apoptosis. Cell. 2010;142:625–636.
   PubMed Web of Science ®Google Scholar
• Revil T, Pelletier J, Toutant J, et al. Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. J Biol Chem. 2009;284:21458–21467.
   PubMed Web of Science ®Google Scholar
• Bae J, Leo C, Hsu S, et al. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem. 2000;275:25255–25261.
   PubMed Web of Science ®Google Scholar
• Bingle C, Craig R, Swales B, et al. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem. 2000;275:22136–22146.
   PubMed Web of Science ®Google Scholar
• Stewart M, Fire E, Keating A, et al. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol. 2010;6:595–601.
   PubMed Web of Science ®Google Scholar
• Venables J, Klinck R, Bramard A, et al. Identification of alternative splicing markers for breast cancer. Cancer Res. 2008;68:9525–9531.
   PubMed Web of Science ®Google Scholar
• Klinck R, Bramard A, Inkel L, et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res. 2008;68:657–663.
   PubMed Web of Science ®Google Scholar
• Gautrey HL, Tyson-Capper AJ. Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS One. 2012;7:e51497.
   PubMed Web of Science ®Google Scholar
• Lin JC, Lin CY, Tarn WY, et al. Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events. Rna. 2014;20:1621–1631.
   PubMed Web of Science ®Google Scholar
• Goodwin CMRO, Olejniczak ET, Fesik SW. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015;22(12):2098–2106.
   PubMed Web of Science ®Google Scholar
• Caputi M, Zahler AM. Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H’/F/2H9 family. J Biol Chem. 2001;276:43850–43859.
   PubMed Web of Science ®Google Scholar
• Huelga SC, Vu AQ, Arnold JD, et al. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012;1:167–178.
   PubMed Web of Science ®Google Scholar
• Wang E, Aslanzadeh V, Papa F, et al. Global profiling of alternative splicing events and gene expression regulated by hnRNPH/F. PLoS ONE. 2012;7:e51266.
   PubMed Web of Science ®Google Scholar
• Gautrey H, Jackson C, Dittrich AL, et al. SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells. RNA Biol. 2015;12:1139–1151.
   PubMed Web of Science ®Google Scholar
• Cartegni L, Wang J, Zhu Z, et al. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003;31:3568–3571.
   PubMed Web of Science ®Google Scholar
• Smith PJ, Zhang C, Wang J, et al. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet. 2006;15:2490–2508.
   PubMed Web of Science ®Google Scholar
• Xiao X, Wang Z, Jang M, et al. Splice site strength-dependent activity and genetic buffering by poly-G runs. Nat Struct Mol Biol. 2009;16:1094–1100.
   PubMed Web of Science ®Google Scholar
• Pino I, Pio R, Toledo G, et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer. 2003;41:131–143.
   PubMed Web of Science ®Google Scholar
• Carpenter B, McKay M, Dundas SR, et al. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer. 2006;95:921–927.
   PubMed Web of Science ®Google Scholar
• Barboro P, Repaci E, Rubagotti A, et al. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer. 2009;100:1608–1616.
   PubMed Web of Science ®Google Scholar
• Matta A, Tripathi SC, DeSouza LV, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer J Inter Du Cancer. 2009;125:1398–1406.
   PubMed Web of Science ®Google Scholar
• Chen LC, Hsueh C, Tsang NM, et al. Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2008;14:3807–3813.
   PubMed Web of Science ®Google Scholar
• Mandal M, Vadlamudi R, Nguyen D, et al. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem. 2001;276:9699–9704.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Ko HL, Goh EH, et al. hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors. Carcinogenesis. 2013;34:1458–1467.
   PubMed Web of Science ®Google Scholar
• Gao FH, Wu YL, Zhao M, et al. Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp Cell Res. 2009;315:3250–3258.
   PubMed Web of Science ®Google Scholar
• Chen LC, Chung IC, Hsueh C, et al. The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ. 2010;17:1463–1473.
   PubMed Web of Science ®Google Scholar
• Venables J, Koh C, Froehlich U, et al. Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol Cell Biol. 2008;28:6033–6043.
   PubMed Web of Science ®Google Scholar
• Honore B, Baandrup U, Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H’ show differential expression in normal and selected cancer tissues. Exp Cell Res. 2004;294:199–209.
   PubMed Web of Science ®Google Scholar
• LeFave CV, Squatrito M, Vorlova S, et al. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. Embo J. 2011;30:4084–4097.
   PubMed Web of Science ®Google Scholar
• Rauch J, O’Neill E, Mack B, et al. Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res. 2010;70:1679–1688.
   PubMed Web of Science ®Google Scholar
• Hope NR, Murray GI. The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol. 2011;42:393–402.
   PubMed Web of Science ®Google Scholar
• Shieh J, Liu K, Huang S, et al. Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J Invest Dermatol. 2009;129:2497–2506.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim J, Park M, et al. Modulation of biological processes in the nucleus by delivery of DNA oligonucleotides conjugated with gold nanoparticles. Biomaterials. 2011;32:2593–2604.
   PubMed Web of Science ®Google Scholar
• Wei G, Margolin AA, Haery L, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21:547–562.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Nimmer P, Sheppard GS, et al. MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther. 2015;14:1837–1847.
   PubMed Web of Science ®Google Scholar
• Anczuków O, Rosenberg A, Akerman M, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012;19:220–228.
   PubMed Web of Science ®Google Scholar